Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Indications for Successful Iron Overload Treatments and Monitoring: Thalassaemia
The increasing efficacy of iron chelation therapy has significantly improved survival of patients with thalassaemia. In this webcast, Maria Domenica Cappellini, MD, reviews expert recommendations for the initiation and monitoring of chelation therapy, as well as what to consider when the need to switch therapy arises.
|
|
Faculty
|
|
|
Maria D. Cappellini, MD
Professor of Internal Medicine
University of Milan
Maggiore Hospital
Milan, Italy
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Utilizing measures of total iron load, including the number of transfusions, serum ferritin levels, and liver iron concentration, in patients with thalassaemia major and intermedia, select appropriate candidates for chelation therapy in order to prevent or reduce iron overload.
- Monitor total iron load in thalassaemia patients who are receiving chelation therapy to ensure that iron taken in via transfusion or gastrointestinal absorption equals iron excreted via chelation to prevent damaging effects of iron overload.
|
Disclosure Information
Maria D. Cappellini, MD, is a consultant for and on the speakers bureau of Novartis Pharmaceuticals Corporation. Prof. Cappellini has disclosed that she will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
